Karim Rahemtulla, Head Fundamental Tactician, Monument Traders Alliance This biotech pick is already a proven winner in our portfolio. Traditionally we would get into a company like this before a big drug is expected to be approved. However, in this case, we are getting into this trade for the momentum. I saw some unusual market activity last week that supports my speculations. What was so unusual about it? Check out the video to find out... |
Tidak ada komentar:
Posting Komentar